Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer
Kymera Therapeutics (NASDAQ: KYMR) has appointed Elaine Caughey as Chief Business Officer, bringing over 20 years of biotechnology experience. Caughey previously held leadership roles at Cygnal Therapeutics and Biogen. CEO Nello Mainolfi expressed confidence in Caughey's capabilities to drive growth in Kymera’s pipeline, particularly in targeted protein degradation. This transition is crucial as multiple clinical programs are expected to advance this year. Founded in 2016, Kymera focuses on innovative small molecule degraders targeting disease-causing proteins, aiming to develop transformative therapies.
- Elaine Caughey's appointment brings over 20 years of relevant experience in biotechnology.
- Caughey's leadership may enhance Kymera's pipeline growth and organizational scaling.
- The company is positioned to advance multiple programs into clinical trials this year.
- Concerns may arise regarding continuity as Caughey transitions into her role.
- Experience gaps may exist given the leadership change.
WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Elaine Caughey, MBA, as Chief Business Officer. Ms. Caughey joins Kymera with over 20 years of experience in the biotechnology industry, including leadership roles in corporate development, business and commercial operations, new product strategy, and investing.
“Elaine brings a broad set of capabilities that will be invaluable in helping Kymera continue to grow our pipeline and scale our organization into a fully integrated degrader medicines company,” said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. “We are excited to have Elaine join the leadership team at Kymera.”
“Kymera’s opportunity to pioneer the targeted protein degradation field and translate this burgeoning field of research into novel therapeutics across several disease areas is very exciting,” said Ms. Caughey. “This is a transformational time for Kymera, with multiple programs expected to move into the clinic this year, and I look forward to helping Kymera realize the potential of this new class of medicines by advancing these programs to market, and ultimately benefitting patients.”
Ms. Caughey joins Kymera with over 20 years of experience in the biotechnology industry. Prior to Kymera, she led business development, strategy and operations as the Chief Business Officer at Cygnal Therapeutics, Inc. Previously, she served as Head of Strategy and Operations, Global Market Access at Biogen, Inc., held senior business development roles at Biogen, Inc. and Cytyc Corporation (acquired by Hologic, Inc.), and held investment roles at the Blackstone Group (formerly Clarus Ventures), MPM Capital, and Advanced Technology Ventures. She holds a Bachelor’s Degree in Economics from Wellesley College and an MBA from Harvard Business School.
About Kymera Therapeutics
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera’s goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.
Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: Pegasus™ platform; and plans and timelines for the clinical development of Kymera Therapeutics' product candidates, including the therapeutic potential and clinical benefits thereof. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of Kymera Therapeutics’ current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company’s planned interactions with regulatory authorities, including the resolution of the current partial clinical hold for KT-474; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the period ended March 31, 2021, filed on May 6, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor Contact:
Paul Cox
VP, Investor Relations and Communications
pcox@kymeratx.com
917-754-0207
Media Contact:
Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
202-930-4762
FAQ
Who is Elaine Caughey and what is her role at Kymera Therapeutics?
What impact could Elaine Caughey's appointment have on Kymera Therapeutics?
When is Kymera Therapeutics planning to advance its clinical programs?
What experience does Elaine Caughey have in the biotechnology field?
